Pfizer's future lead obesity candidate from Metsera needs to match Zepbound

Upcoming early results from a handful of Phase 2b trials of Metsera’s GLP-1 drug in obesity would have been make-or-break for the newly-public biotech. But now, after Pfizer announced on Monday it was buying it ...